Innovation Made in Italy Poised to Enter the Cell and Gene Therapy Market
Related Vendors
Innovation in high technology and Italian hospitality — now IMA Group rises the next level. Following acquisitions and in-house developments, IMA has evolved into a one-stop-shop supplier, says Thomas Fricke, Commercial Director o IMA Pharma. At Achema IMA presents a developement opening up the cell- and gene therapy market.
The theme for the IMA Group at the memorable August Achema 2022 was „All in one Pharma”, and this year, the Italian machinery manufacturer is showcasing the same catchy theme at both its booth and online presence. Thomas Fricke, Commercial Director of IMA Pharma, appeared in good spirits for an interview about the last two years. IMA’s presence at the show is being well received. Their stand, measuring 1,400 square meters, is one of the largest at the event. In its three sections, the company is displaying a variety of new developments, including the Nebula, the fastest decontamination tunnel ever created, and a highly confidential machinery concept for the production of cell and gene therapeutics. Upon entering the spacious trade show cafeteria, visitors are greeted by a cacophony of multilingual chatter. By the end of the event, the hospitable hostesses will have served 62,000 cups of coffee to visitors.
“We have made significant progress on our path to becoming a one-stop-shop supplier,” says Fricke. “What we are showcasing here at the trade fair are true showcases of completed projects,” he emphasizes. For instance, visitors can see a fully automated assembly machine for autoinjectors, which can be completed with the appropriate packaging up to the pallet stage. Through acquisitions, new machines and suppliers have been added to the portfolio. “And we have developed machines that were missing, such as a high-speed labeling machine, allowing us to now offer complete lines to our customers,” Fricke explains.
Sign in or register and read on
Please log in or register and read this article. To be able to read this article in full, you must be registered. Free registration gives you access to exclusive specialist information.
Already registered? Log in here